title: G-CSF primed peripheral blood progenitor cells in autologous bone marrow transplantation: parameters affecting bone marrow engraftment.
abstract: G-CSF and GM-CSF enhance the rate of neutrophil engraftment in autologous bone marrow transplantation (ABMT) without significantly affecting platelet engraftment. Peripheral blood progenitor cells (PBPC) may enhance rates of engraftment of both neutrophils and platelets. We treated 49 patients undergoing ABMT with a course of G-CSF to obtain PBPC and infused these cells post-transplant with G-CSF in an attempt to determine factors which might correlate with enhanced BM engraftment. Forty-nine patients with Hodgkin's disease, non-Hodgkin's lymphoma or breast cancer undergoing unpurged ABMT were studied. G-CSF priming consisted of an outpatient 8 day course of 5 micrograms/kg/day followed by three leukaphereses (on day 5, 7 and 8) to collect PBPC. Patients then received a chemotherapeutic BMT preparative regimen followed by an infusion of PBPC, autologous BM and the reinstitution of G-CSF (16 micrograms/kg/day). BM engraftment was rapid. The median time to achieve 0.5 x 10(9)/l neutrophils was 10 days compared with a historical BMT control patient population receiving the same preparative regimens of 19 days (p = 0.001). Time to achieve a platelet count of 20 x 10(9)/l was 16 days compared with a historical control of 22 days (p = 0.001). Neutrophil engraftment occurred in all patients by day +14. Marrow engraftment correlated with the total number of CD34+ cells infused as well as the total number of mononuclear cells infused but not the total number of CD34+/CD33- cells infused. The amount of total blood volume pheresed significantly correlated with yield of total mononuclear cells. Prior exposure to radiation therapy negatively correlated with progenitor cell yield.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Hematology/Oncology, Cleveland Clinic Foundation, OH 44195.
authors.forename: B J
authors.initials: BJ
authors.lastname: Bolwell
authors.forename: A
authors.initials: A
authors.lastname: Fishleder
authors.forename: S W
authors.initials: SW
authors.lastname: Andresen
authors.forename: A E
authors.initials: AE
authors.lastname: Lichtin
authors.forename: A
authors.initials: A
authors.lastname: Koo
authors.forename: T
authors.initials: T
authors.lastname: Yanssens
authors.forename: R
authors.initials: R
authors.lastname: Burwell
authors.forename: P
authors.initials: P
authors.lastname: Baucco
authors.forename: R
authors.initials: R
authors.lastname: Green
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006085:Graft Survival / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006410:Hematopoiesis; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006689:Hodgkin Disease / Q000188:drug therapy / Q000601:surgery; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D014182:Transplantation, Autologous
chemical_list: D016179:Granulocyte Colony-Stimulating Factor